ArticleVeterinary research2015
Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in viral pathogenesis and immune protection.
Article in Veterinary research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 93 citations in OpenAlex.
- Correlates of protection against African swine fever virus identified by a systems immunology approach.eLife · 2026Article
- Advances in African swine fever vaccine development: challenges and prospects.Journal of veterinary science · 2026Review
- Recombinant vaccinia vectored ASFV vaccine enhances swine survival against genotype II challenge.NPJ vaccines · 2026Article
- Intranasal inoculation with African swine fever virus genotype II reveals dose-dependent infectivity, pathogenesis and diagnostic challenges in pigs.The veterinary quarterly · 2025Article
- Designing a multi-epitope vaccine against African swine fever virus using immunoinformatics approach.Scientific reports · 2025Article
- Generation of Chimeric African Swine Fever Viruses ThroughVaccines · 2025Article
- Identification ofMicrobiology spectrum · 2025Article
- Article
- Comprehensive Characterization of the Genetic Landscape of African Swine Fever Virus: Insights into Infection Dynamics, Immunomodulation, Virulence and Genes with Unknown Function.Animals : an open access journal from MDPI · 2024Review
- Article
- The transcriptomic insight into the differential susceptibility of African Swine Fever in inbred pigs.Scientific reports · 2024Article
- Article
- Defining correlates of protection for mammalian livestock vaccines against high-priority viral diseases.Frontiers in immunology · 2024Review
- Review
- Combinational Deletions ofJournal of virology · 2023Article
- A study of African swine fever virus in Regional VI of the Disease Investigation Center of Denpasar Bali in Indonesia.Veterinary world · 2023Article
- Attenuated African swine fever virus through serial passaging of viruses in cell culture: a brief review on the knowledge gathered during 60 years of research.Virus genes · 2023Review
- Review
- Vaccines for African swine fever: an update.Frontiers in microbiology · 2023Review
- African swine fever control and prevention: an update on vaccine development.Emerging microbes & infections · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) is the causal agent of African swine fever, a hemorrhagic and often lethal porcine disease causing enormous economical losses in affected countries. Endemic for decades in most of the sub-Saharan countries and Sardinia, the risk of ASFV-endemicity in Europe has increased since its last introduction into Europe in 2007. Live attenuated viruses have been demonstrated to induce very efficient protective immune responses, albeit most of the time protection was circumscribed to homologous ASFV challenges. However, their use in the field is still far from a reality, mainly due to safety concerns. In this study we compared the course of the in vivo infection caused by two homologous ASFV strains: the virulent E75 and the cell cultured adapted strain E75CV1, obtained from adapting E75 to grow in the CV1 cell-line. Interestingly, the kinetics of both viruses not only differed on the clinical signs that they caused and in the virus loads found, but also in the immunological pathways activated throughout the infections. Furthermore, E75CV1 confirmed its protective potential against the homologous E75 virus challenge and allowed the demonstration of poor cross-protection against BA71, thus defining it as heterologous. The in vitro specificity of the CD8(+) T-cells present at the time of lethal challenge showed a clear activation against the homologous virus (E75) but not against BA71. These findings will be of utility for a better understanding of ASFV pathogenesis and for the rational designing of safe and efficient vaccines against this virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.